William Blair Has Bullish Estimate for CRL Q2 Earnings

Charles River Laboratories International, Inc. (NYSE:CRL) – Analysts at William Blair upped their Q2 2025 earnings per share estimates for Charles River Laboratories International in a report released on Wednesday, May 7th. William Blair analyst M. Smock now expects that the medical research company will earn $2.49 per share for the quarter, up from their prior forecast of $2.40. William Blair has a “Market Perform” rating on the stock. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $9.36 per share. William Blair also issued estimates for Charles River Laboratories International’s Q4 2025 earnings at $2.52 EPS, FY2025 earnings at $9.79 EPS and FY2026 earnings at $10.83 EPS.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, beating analysts’ consensus estimates of $2.06 by $0.28. The business had revenue of $984.17 million during the quarter, compared to the consensus estimate of $942.34 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.27 EPS.

Several other research firms have also weighed in on CRL. JPMorgan Chase & Co. lowered their price objective on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a research note on Thursday, February 20th. Redburn Atlantic raised shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price target for the company in a research note on Monday, March 3rd. Robert W. Baird upped their price objective on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the company a “neutral” rating in a report on Thursday. Mizuho reduced their target price on Charles River Laboratories International from $175.00 to $155.00 and set a “neutral” rating for the company in a research note on Wednesday, April 9th. Finally, Evercore ISI raised Charles River Laboratories International from an “in-line” rating to an “outperform” rating and set a $170.00 price target on the stock in a research note on Thursday. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $176.00.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $138.84 on Monday. The firm’s fifty day simple moving average is $138.40 and its two-hundred day simple moving average is $166.20. Charles River Laboratories International has a 12 month low of $91.86 and a 12 month high of $254.15. The stock has a market capitalization of $6.82 billion, a P/E ratio of 925.60, a price-to-earnings-growth ratio of 4.54 and a beta of 1.50. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65.

Insiders Place Their Bets

In other Charles River Laboratories International news, COO Birgit Girshick acquired 1,514 shares of the business’s stock in a transaction on Thursday, February 20th. The shares were acquired at an average price of $164.63 per share, with a total value of $249,249.82. Following the completion of the transaction, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. This trade represents a 2.83% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the firm’s stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the sale, the executive vice president now directly owns 20,013 shares of the company’s stock, valued at approximately $3,252,112.50. This represents a 18.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Charles River Laboratories International

A number of hedge funds have recently modified their holdings of CRL. Rothschild Investment LLC grew its holdings in Charles River Laboratories International by 480.0% during the first quarter. Rothschild Investment LLC now owns 174 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 144 shares during the period. HM Payson & Co. purchased a new position in shares of Charles River Laboratories International during the 1st quarter valued at $31,000. Pinnacle Bancorp Inc. lifted its position in shares of Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after buying an additional 65 shares during the last quarter. Optiver Holding B.V. bought a new position in shares of Charles River Laboratories International during the 4th quarter worth $37,000. Finally, GeoWealth Management LLC increased its holdings in Charles River Laboratories International by 311.5% in the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company’s stock worth $46,000 after acquiring an additional 190 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).